UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy

Autor: P, Diez, G G, Hanna, K L, Aitken, N, van As, A, Carver, R J, Colaco, J, Conibear, E M, Dunne, D J, Eaton, K N, Franks, J S, Good, S, Harrow, P, Hatfield, M A, Hawkins, S, Jain, F, McDonald, R, Patel, T, Rackley, P, Sanghera, A, Tree, L, Murray

Publikováno v: Diez, P, Hanna, G G, Aitken, K L, van As, N, Carver, A, Colaco, R J, Conibear, J, Dunne, E M, Eaton, D J, Franks, K N, Good, J S, Harrow, S, Hatfield, P, Hawkins, M A, Jain, S, McDonald, F, Patel, R, Rackley, T, Sanghera, P, Tree, A & Murray, L 2022, ' UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy ', Clinical oncology (Royal College of Radiologists (Great Britain)), vol. 34, no. 5, pp. 288-300 . https://doi.org/10.1016/j.clon.2022.02.010

The use of stereotactic ablative radiotherapy (SABR) in the UK has expanded over the past decade, in part as the result of several UK clinical trials and a recent NHS England Commissioning through Evaluation programme. A UK SABR Consortium consensus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31d8facd83767907e3e94c40e5d722b4
https://pure.qub.ac.uk/en/publications/6771a69c-358d-40d8-99ab-dfe5aa026056